In vitro effect of new formulations of amphotericin B on amastigote and promastigote forms of Leishmania infantum.
作者： Lara Ordóñez-Gutiérrez , Raquel Espada-Fernández , María Auxiliadora Dea-Ayuela , Juan José Torrado , Francisco Bolás-Fernandez
DOI: 10.1016/J.IJANTIMICAG.2007.05.013
关键词:
摘要: Abstract The in vitro antileishmanial activities of various new amphotericin B (AMB) formulations were investigated, including microspheres hydrophilic albumin with three AMB aggregation forms (monomeric, dimeric and multiaggregate) the polymers polylactic-co-glycolic acid, Resomer RG502 RG503 multiaggregate form. This study was performed on extracellular promastigote form intracellular amastigote a canine strain Leishmania infantum (UCM 20) using infected J774 murine macrophage-like cell line. Albumin-encapsulated did not show any toxicity for cells had lower median effective concentration (EC 50 ) values (ca. 0.003 μg/mL) L. amastigotes than free (0.03 μg/mL). In addition, state notable effect activity drug. Results obtained point towards interest monomeric encapsulated chemotherapeutic control leishmaniasis.
elsevier.com
sci-hub.se 参考文章(33)
Marco Antonio Moreno, Paloma Frutos, Ma Paloma Ballesteros, Lyophilized lecithin based oil-water microemulsions as a new and low toxic delivery system for amphotericin B. Pharmaceutical Research. ,vol. 18, pp. 344- 351 ,(2001) , 10.1023/A:1011011215418
R. Badaro, K. Weerasuriya, C. P. Thakur, L. Pang, K. Behbehani, F. Kuzoe, R. Davidson, J. D. Berman, A. D. M. Bryceson, K. M. Wasunna, Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bulletin of The World Health Organization. ,vol. 76, pp. 25- 32 ,(1998)
Simon L Croft, Shyam Sundar, Alan H Fairlamb, None, Drug Resistance in Leishmaniasis Clinical Microbiology Reviews. ,vol. 19, pp. 111- 126 ,(2006) , 10.1128/CMR.19.1.111-126.2006
Roberto Badaró, Heonir Rocha, EdgarM. Carvalho, AristidesC. Queiroz, ThomasC. Jones, Leishmania donovani: an opportunistic microbe associated with progressive disease in three immunocompromised patients. The Lancet. ,vol. 327, pp. 647- 649 ,(1986) , 10.1016/S0140-6736(86)91725-3
J. D. Berman, D. J. Wyler, An in Vitro Model for Investigation of Chemotherapeutic Agents in Leishmaniasis The Journal of Infectious Diseases. ,vol. 142, pp. 83- 86 ,(1980) , 10.1093/INFDIS/142.1.83
Gad Baneth, Susan E Shaw, Chemotherapy of canine leishmaniosis. Veterinary Parasitology. ,vol. 106, pp. 315- 324 ,(2002) , 10.1016/S0304-4017(02)00115-2
Judith Mikus, Dietmar Steverding, A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue. Parasitology International. ,vol. 48, pp. 265- 269 ,(2000) , 10.1016/S1383-5769(99)00020-3
Jonathan D. Berman, U.S Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clinical Infectious Diseases. ,vol. 28, pp. 49- 51 ,(1999) , 10.1086/515086
D.T. Hart, G.H. Coombs, Leishmania mexicana: energy metabolism of amastigotes and promastigotes. Experimental Parasitology. ,vol. 54, pp. 397- 409 ,(1982) , 10.1016/0014-4894(82)90049-2
J. A. Sánchez-Brunete, M. A. Dea, S. Rama, F. Bolás, J. M. Alunda, S. Torrado-Santiago, J. J. Torrado, Influence of the vehicle on the properties and efficacy of microparticles containing amphotericin B. Journal of Drug Targeting. ,vol. 13, pp. 225- 233 ,(2005) , 10.1080/10611860500097107